Key result
Bovine jugular vein conduits carry a ~6% infective endocarditis risk, exceeding homografts and ePTFE.
Why the study?
Homograft, bovine jugular vein, and ePTFE are commonly used valved conduits for RVOT reconstruction, but their relative performance remained unclear.
Do bovine jugular vein and ePTFE valved conduits have comparable mortality, replacement rates, and infective endocarditis incidence compared to homograft in patients undergoing right ventricular outflow tract reconstruction?
Do bovine jugular vein and ePTFE valved conduits have comparable mortality, replacement rates, and infective endocarditis incidence compared to homograft in patients undergoing right ventricular outflow tract reconstruction?
Bovine jugular vein and ePTFE are viable alternatives to homograft for RVOT reconstruction with comparable mortality and replacement rates, though BJV carries a significantly higher risk of infective endocarditis.
Answers are grounded in this paper and cite their sources.
Supports heightened IE surveillance with bovine jugular vein conduits; leaves open optimal choice pending randomized trials.
Background: Homograft, bovine jugular vein (BJV) and expanded polytetrafluoroethylene (ePTFE) valved conduits are most common valved conduits for reconstructing right ventricular outflow tracts (RVOT), while the performance of those three valved conduits was still unclear. Materials and methods: We searched Ovid MEDLINE, Ovid Embase, as well as Chinese databases of SinoMed, CNKI, and Wanfang from 1 January 2000 to 26 August 2024 to identify studies on RVOT reconstruction with homograft, BJV, and ePTFE valved conduits. We included studies reporting the outcomes of mortality, replacement rate, and the incidence of infective endocarditis. The “meta” and “metafor” packages in R version 4.2.1 were used for evidence synthesis. ROBINS-I tool was used for assessing the risk of bias. This study is registered on PROSPERO (CRD42024582184). Results: According to 28 retrospective cohort studies ( n = 3966), there was no significant difference in mortality and replacement rate between homograft, BJV, and ePTFE. However, the IE incidence in BJV was significantly higher than that in homograft (RR = 3.63, 95% CI: 1.69–7.83, P < 0.01). Based on the pooled results of 113 case-series reports ( n = 16 367), the total mortality of homograft, BJV, and ePTFE was 8% (95% CI: 6%–9%), 5% (95% CI: 4%–7%), and 3% (95% CI: 3%–4%), respectively. The replacement rate of homograft, BJV, and ePTFE was 9% (95% CI: 6%–13%), 9% (95% CI:6%–12%), and 4% (95% CI: 2%–9%), respectively. The incidence of IE for BJV was 6% (95% CI: 3%–10%), which was higher than 2% for homograft (95% CI: 1%–4%) and 1% for ePTFE (95% CI: 1%–2%). Conclusions: While BJV and ePTFE are viable alternatives with comparable mortality and replacement rate to homograft, the elevated IE risk in BJV necessitates cautious patient selection and monitoring.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question. Bovine jugular vein conduits had a higher incidence of infective endocarditis compared to homografts and ePTFE, posing a risk that requires careful monitoring.
Synapse has enriched 10 related papers. Consider them for comparative context: